Tag search results
Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.
Sandoz will sell a pair of injectors, under the name Symjepi, for $250 without insurance.
Idaho is getting roughly $483,000 from EpiPen maker Mylan as part of a multi-state settlement.
The makers of the EpiPen failed to properly investigate more than 100 complaints that the device misfired during life-threatening emergencies -- including situations in which patients later died, according to a Food and Drug Administration letter.
Mylan’s $465 million settlement of a U.S. case that claimed the drugmaker defrauded taxpayers by misclassifying its allergy-shot EpiPen product as a generic drug was finalized by the Justice Department.
U.S. regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed. As the mom of a kid with severe peanut/nut allergies this is welcome news. Do you or anyone in your family need to carry ah Epi-Pen?
The agency on Thursday approved Adamis Pharmaceuticals Corp.’s product, which should go on sale later this year.
Recent legislation in the U.S. Senate and in the Washington Legislature may eventually shine a brighter light on pricing practices.
CVS is now selling a rival, generic version of Mylan’s EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to consumers.
A key feature of Republican plans to replace Obamacare is allowing market forces to boost innovation and competition among health care providers. “Unleashing the power of choice and competition is the best way to lower health care costs and improve quality,” declares House Speaker Paul Ryan in his conservative manifesto “A Better Way.”
Months after promised, Mylan launched a half-priced authorized generic of EpiPen, the lifesaving allergy injection that drew political ire for its dramatic price increases.
Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.
President-elect Donald Trump’s victory Tuesday has prompted embattled pharmaceutical executive Martin Shkreli to publicly debut some songs off the one-of-a-kind Wu-Tang Clan album he bought for $2 million last year.
Lawmakers were skeptical last week when Mylan chief executive Heather Bresch said that the company made only $100 in profit for a two-pack of EpiPens. During a House hearing, Bresch repeatedly referred to a poster board showing how little of the $608 list price trickled back to the company.
Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its lifesaving EpiPens and the profits for a company with sales in excess of $11 billion.
New York’s attorney general says his office is investigating Mylan Pharmaceuticals, which has been criticized for steep price increases for its emergency allergy treatment EpiPen.
The reality is that patients in other countries are charged less for health care services and drugs across the board, because their governments make it so.
Mylan, the giant pharmaceutical company, has gotten tons of grief lately for jacking up the price of its lifesaving EpiPen. What you might not know is that Mylan moved it corporate base to the Netherlands last year to reduce its U.S. income taxes.
Spokane resident Zach Shallbetter wrote this opinion column about his reliance on EpiPens and his opinion of their dramatic price increase. It originally appeared on the website Medium.
Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients.